Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model
Sensitivity and scenario analyses, including more frequent SGLT2 inhibitor use consistent with real-world data, indicate a robust ICER that remains within the bounds of what is typically considered cost-effective.
Authors
- Stephen Morris (ORCID: https://orcid.org/0000-0002-5828-3563)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- A. Millier
- Michał Pochopień
- Sean D. Sullivan (ORCID: https://orcid.org/0000-0003-3052-6540)
- Prabir Roy‐Chaudhury (ORCID: https://orcid.org/0000-0002-7970-7302)
- Aleksandra Drzewiecka‐Antonik (ORCID: https://orcid.org/0000-0003-3396-8571)
- Paul Mernagh
- Kerstin Folkerts
- Pierre Lévy (ORCID: https://orcid.org/0000-0001-7565-2255)
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- University of Washington (US)
- University of Cambridge (GB)
- W. G. (Bill) Hefner VA Medical Center (US)
- Laboratoire d’Economie de Dauphine (FR)
- Creativ-Ceutical (France) (FR)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Université Paris Dauphine-PSL (FR)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1080/13696998.2025.2451526
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47